Staphylococcus aureus develops increased resistance to antibiotics by forming dynamic small colony variants during chronic osteomyelitis

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 2, 2016, Pages 438-448

  Tuchscherr, L ^a   Kreis, C A ^b   Hoerr, V ^a,b   Flint, L ^b   Hachmeister, M ^b   Geraci, J ^a   Bremer Streck, S ^a   Kiehntopf, M ^a   Medina, E ^c   Kribus, M ^a   Raschke, M ^b   Pletz, M ^a   Peters, G ^b   Loffler B ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFUROXIME; CLINDAMYCIN; DAPTOMYCIN; FOSFOMYCIN; GENTAMICIN; LINEZOLID; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; BACTERIUM COLONY; BONE DEFORMATION; CHRONIC OSTEOMYELITIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMATOGENOUS OSTEOMYELITIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; OSTEOBLAST; PHENOTYPE; STAPHYLOCOCCUS AUREUS; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; CELL CULTURE; CHRONIC DISEASE; DISEASE MODEL; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; MICROBIOLOGY; OSTEOMYELITIS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; CELLS, CULTURED; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MICE, INBRED C57BL; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOMYELITIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84959916703     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv371     Document Type: Article

References (53)

1. Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004; 364: 369-79.
2. Shetty AK, Kumar A. Osteomyelitis in adolescents. Adolesc Med State Art Rev 2007; 18: 79-94, ix.
3. Trampuz A, Zimmerli W. Diagnosis and treatment of infections associated with fracture-fixation devices. Injury 2006; 37 Suppl 2: S59-66.
4. Berendt AR, Peters EJ, Bakker K et al. Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev 2008; 24 Suppl 1: S145-61.
5. Sheehy SH, Atkins BA, Bejon P et al. The microbiology of chronic osteomyelitis: prevalence of resistance to common empirical anti-microbial regimens. J Infect 2010; 60: 338-43.
6. Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis 2012; 54: 393-407.
7. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 520-32.
8. Proctor RA, von EiffC, Kahl BC et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 2006; 4: 295-305.
9. Tuchscherr L, Heitmann V, HussainM et al. Staphylococcus aureus smallcolony variants are adapted phenotypes for intracellular persistence. J Infect Dis 2010; 202: 1031-40.
10. Garcia LG, Lemaire S, Kahl BC et al. Antibiotic activity against smallcolony variants of Staphylococcus aureus: review of in vitro, animal and clinical data. J Antimicrob Chemother 2013; 68: 1455-64.
11. Nguyen HA, Denis O, Vergison A et al. Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normalphenotype and revertant strains. Antimicrob Agents Chemother 2009; 53: 1434-42.
12. Balaban NQ, Merrin J, Chait R et al. Bacterial persistence as a phenotypic switch. Science 2004; 305: 1622-5.
13. Kriegeskorte A, Konig S, Sander G et al. Small colony variants of Staphylococcus aureus reveal distinct protein profiles. Proteomics 2011; 11: 2476-90.
14. Tuchscherr L, Medina E, Hussain M et al. Staphylococcus aureus phenotype switching: an effective bacterial strategy to escape host immune response and establish a chronic infection. EMBO Mol Med 2011; 3: 129-41.
15. Tuchscherr L, BischoffM, Lattar SM et al. Sigma factor SigB is crucial to mediate Staphylococcus aureus adaptation during chronic infections. PLoS Pathog 2015; 11: e1004870.
16. Edwards AM. Phenotype switching is a natural consequence of Staphylococcus aureus replication. J Bacteriol 2012; 194: 5404-12.
17. Vesga O, Groeschel MC, Otten MF et al. Staphylococcus aureus small colony variants are induced by the endothelial cell intracellular milieu. J Infect Dis 1996; 173: 739-42.
18. Massey RC, Buckling A, Peacock SJ. Phenotypic switching of antibiotic resistance circumvents permanent costs in Staphylococcus aureus. Curr Biol 2001; 11: 1810-4.
19. Ambrosch A, Haefner S, Jude E et al. Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus. IntWound J 2011; 8: 567-77.
20. Morgan M. Treatment of MRSA soft tissue infections: an overview. Injury 2011; 42 Suppl 5: S11-7.
21. Fraimow HS. Systemic antimicrobial therapy in osteomyelitis. Semin Plast Surg 2009; 23: 90-9.
22. Perlroth J, Kuo M, Tan J et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008; 168: 805-19.
23. Zimmerli W, Widmer AF, Blatter M et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998; 279: 1537-41.
24. Ellington JK, Reilly SS, Ramp WK et al. Mechanisms of Staphylococcus aureus invasion of cultured osteoblasts. Microb Pathog 1999; 26: 317-23.
25. Ellington JK, Harris M, Hudson MC et al. Intracellular Staphylococcus aureus and antibiotic resistance: implications for treatment of staphylococcal osteomyelitis. J Orthop Res 2006; 24: 87-93.
26. Carryn S, Chanteux H, Seral C et al. Intracellular pharmacodynamics of antibiotics. Infect Dis Clin North Am 2003; 17: 615-34.
27. Van Bambeke F, Barcia-Macay M, Lemaire S et al. Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Curr Opin Drug Discov Devel 2006; 9: 218-30.
28. Balwit JM, van Langevelde P, Vann JM et al. Gentamicin-resistant menadione and hemin auxotrophic Staphylococcus aureus persist within cultured endothelial cells. J Infect Dis 1994; 170: 1033-7.
29. Kahl B, Herrmann M, Everding AS et al. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis 1998; 177: 1023-9.
30. von EiffC, Bettin D, Proctor RA et al. Recovery of small colony variants of Staphylococcus aureus following gentamicin bead placement for osteomyelitis. Clin Infect Dis 1997; 25: 1250-1.
31. Johansson A, Flock JI, Svensson O. Collagen and fibronectin binding in experimental staphylococcal osteomyelitis. Clin Orthop Relat Res 2001: 241-6.
32. Barcia-Macay M, Seral C, Mingeot-Leclercq MP et al. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother 2006; 50: 841-51.
33. Lode H, Kemmerich B, Koeppe P. [Comparative clinical pharmacology of gentamicin, sisomicin, and tobramycin]. Antimicrob Agents Chemother 1975; 8: 396-401.
34. Viberg A, Lannergard A, Larsson A et al. A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function. Br J Clin Pharmacol 2006; 62: 297-303.
35. Frossard M, Joukhadar C, Erovic BM et al. Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. Antimicrob Agents Chemother 2000; 44: 2728-32.
36. Goto M, Sugiyama M, Nakajima S et al. Fosfomycin kinetics after intravenous and oral administration to human volunteers. Antimicrob Agents Chemother 1981; 20: 393-7.
37. Harle A, RitzerfeldW. The release of gentamycin into the wound secretions from polymethylmethacrylate beads. A study with reference to the animal experiment. Arch Orthop Trauma Surg 1979; 95: 65-70.
38. Salvati EA, Callaghan JJ, Brause BD et al. Reimplantation in infection. Elution of gentamicin from cement and beads. Clin Orthop Relat Res 1986; 207: 83-93.
39. 1. Cell Microbiol 1999; 1: 101-17.
40. Kusuma CM, Kokai-Kun JF. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 3256-63.
41. DeHaan RM, Metzler CM, Schellenberg D et al. Pharmacokinetic studies of clindamycin phosphate. J Clin Pharmacol 1973; 13: 190-209.
42. Horst SA, Hoerr V, Beineke A et al. A novelmousemodelof Staphylococcus aureus chronic osteomyelitis that closely mimics the human infection: an integrated view of disease pathogenesis. Am J Pathol 2012; 181: 1206-14.
43. Cherlet M, Baere SD, Backer PD. Determination of gentamicin in swine and calf tissues by high-performance liquid chromatography combined with electrospray ionization mass spectrometry. J Mass Spectrom 2000; 35: 1342-50.
44. de Velde F, Alffenaar JW, Wessels AM et al. Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 1771-7.
45. Partani P, Gurule S, Khuroo A et al. Liquid chromatography/electrospray tandem mass spectrometry method for the determination of cefuroxime in human plasma: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 428-34.
46. Garzoni C, Kelley WL. Staphylococcus aureus: new evidence for intracellular persistence. Trends Microbiol 2009; 17: 59-65.
47. Proctor RA, van Langevelde P, KristjanssonM. et al. Persistent andrelapsing infections associated with small-colony variants of Staphylococcus aureus. Clin Infect Dis 1995; 20: 95-102.
48. Valour F, Trouillet-Assant S, Riffard N et al. Antimicrobial activity against intraosteoblastic Staphylococcus aureus. Antimicrob Agents Chemother 2015; 59: 2029-36.
49. Mitchell G, Lamontagne CA, Brouillette E et al. Staphylococcus aureus SigB activity promotes a strong fibronectin-bacterium interaction which may sustain host tissue colonization by small-colony variants isolated from cystic fibrosis patients. Mol Microbiol 2008; 70: 1540-55.
50. Chuard C, Vaudaux PE, Proctor RA et al. Decreased susceptibility to antibiotic killing of a stable small colony variant of Staphylococcus aureus in fluid phase and on fibronectin-coated surfaces. J Antimicrob Chemother 1997; 39: 603-8.
51. Brady RA, Leid JG, Calhoun JH et al. Osteomyelitis and the role of biofilms in chronic infection. FEMS Immunol Med Microbiol 2008; 52: 13-22.
52. Landersdorfer CB, Bulitta JB, Kinzig M et al. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet 2009; 48: 89-124.
53. Diefenbeck M, Muckley T, Hofmann GO. Prophylaxis and treatment of implant-related infections by local application of antibiotics. Injury 2006; 37 Suppl 2: S95-104.